ONCOLOGY

Dr Miguel Jorge said the physician-patient relationship requires enough time at each contact to allow for a comprehensive person-centred approach to care.

4.5% increase in invasive DFS in node-positive subgroup did not meet significance but still relevant.

Achieves 15-month duration of response but deaths from interstitial lung disease remain a concern.

Japanese phase 3 POTENT trial reported 39% reduction in disease recurrence.

OS in phase 2 HER2CLIMB was 4.5 months longer vs placebo.

Rechallenge can improve outcomes when later line novel therapies are not available.

Phase 3 trial of 4000 women randomly assigned to denosumab or placebo.

Results from the ICON8 trial have been published in the Lancet.

Phase 1 trial finds good objective response rates and PFS in EGFR-mutated NSCLC with leptomeningeal metastases.

Preclinical studies as well as studies in breast cancer suggest that dual HER2 therapy might improve outcomes.

Comparable rates of response at cycle 6.

Analysis of risk factors can help guide patient management.

Jon is an Emergency Medicine Doctor at St Mary's Hospital in London, and has a particular interest in organisational management and planning. He has an MBA and a PG certificate in innovation, and is interested in teaching and research. He is married to an anaesthetist and enjoys running, cycling and skiing.

The platform will expedite submission to 17 affiliate journals.